Why this Houston medical device innovator is pumped up for the first total artificial heart

HOUSTON INNOVATORS PODCAST EPISODE 248

Dr. William Cohn is the chief medical officer for BiVACOR, a medical device company creating the first total artificial heart. Photo via TMC

It's hard to understate the impact Dr. William Cohn has had on cardiovascular health as a surgeon at the Texas Heart Institute or on health care innovation as the director of the Center for Device Innovation at the Texas Medical Center. However, his role as chief medical officer of BiVACOR might be his most significant contribution to health care yet.

The company's Total Artificial Heart is unlike any cardiovascular device that's existed, Cohn explains on the Houston Innovators Podcast. While most devices are used temporarily for patients awaiting a heart transplant, BiVACOR's TAH has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

"Artificial hearts historically have had bladders that ejected and filled 144,000 times a day. They work great for temporary support, but no one is suggesting they are permanent devices," Cohn says on the show.

The difference with BiVACOR's device is it abandons the bladder approach. Cohn explains that as assist pumps evolved — something his colleague, Dr. Bud Frasier, had a huge impact on — they featured new turbine and rotor technology. Daniel Timms, BiVACOR's founder and CTO, iterated on this technology beginning when he was a postdoctoral student at Queensland University of Technology in Australia.

"BiVACOR is the first artificial heart that leverages what we learned from that whole period — it has no bladders, it has no valves. It has one moving part, and that moving part is suspended in an electromagnetic field controlled by a computer and changed thousands of times a second," Cohn says. "It will never wear out, and that's why we think it's the world's first total artificial heart."

The company is seeing momentum, celebrating its first successful human implantation last month. The device was used for eight days on a patient at Baylor St. Luke’s Medical Center before the patient received a heart transplant.

Cohn says that BiVACOR has plans to use the TAH as "bridge-to-transplant" device in several other surgeries and expects to get FDA approval for that purpose in the next three to four years before working toward clearance for total artificial heart transplants.

Cohn has worked to support medical device startups at CDI at TMC for the seven years it has existed — first under Johnson and Johnson and then under TMC when it took the program over. He describes the center and its location as the ideal place for developing the future of health care, with Houston rising up to compete with regions known for medical device success — both coasts and Minnesota.

"Being in the shadow of the largest medical center on the planet — 106,000 employees show up there every 24 hours," Cohn says, "if you want to innovate, this is the place to do it."

From Your Site Articles
Revisiting a conversation with Dr. Joseph Rogers, president and CEO of the Texas Heart Institute, on the Houston Innovators Podcast. Photo via texasheart.org

Play it back: How this Houstonian is leading heart health innovation

HOUSTON INNOVATORS PODCAST EPISODE 246

Heart health innovation is at a major moment in history — and Houston is at the center of it.

Last summer, Dr. Joseph Rogers, president and CEO of the Houston-based Texas Heart Institute, joined the Houston Innovators Podcast to share how he came to be at the helm of THI, as well as the incredible technologies the institute is working on to address heart failure, a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the U.S.

This month, one of THI’s technologies reached a major milestone. BiVACOR, a Houston company successfully implanted the company's first Total Artificial Heart in a human. The device was implanted in the patient on July 9. Eight days later, a donor heart became available and was transplanted into the patient, removing the TAH, establishing the device as a successful bridge-to-heart-transplant solution for patients, THI reported.

In addition to this breakthrough in health tech, THI is focused on addressing Cardiometabolic Syndrome at a new conference on Friday, August 23, in Houston. The full-day symposium will take place in collaboration with Arianna Huffington, the founder and CEO of Thrive Global. Dr. Rogers is co-directing the program with Dr. Stephanie Coulter, medical director for THI Center for Women’s Heart & Vascular Health.


In the episode, Rogers explains why he's bullish on Houston and THI leading heart health innovation alongside other health care organizations — nonprofits, universities, local government — to collaborate in ways never been done before. And THI is dedicated to this mission.

"We should act as a convener," Rogers says. "Houston is the place to do this.

"The reason I think this is such an important community to address this problem is it's the most diverse city in the United States. And I've never lived anywhere or heard of another city that I was so convinced believed they could do anything they set their minds to. It's about making the community aware of the problem and a potential solution — and then working on trying to solve it," he continues. "But I think all of the pieces are here to show the world how to do this at a community level."

Emerson Perin of the Texas Heart Institute, recently published the largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America. Photo via texasheart.org

Houston health care leader on a mission to innovate an end to heart failure

cardiology cured

Emerson Perin’s end goal isn’t to treat heart failure. The medical director of The Texas Heart Institute says that he has his sights set firmly on curing the malady altogether. And, with the power of innovation and a strong team, the Houston-based cardiologist has a good chance of meeting his objective.

Perin first came to THI for fellowship training in 1988, following his residency in Miami and medical school in his birthplace of Brazil.

“This is a very special place,” the physician and researcher, whose titles also include director for THI’s Center for Clinical Research and vice president for medical affairs, tells InnovationMap. “It has a worldwide-reaching reputation. I’ve always liked research and this is a great place in terms of innovation and practicing high-level cardiology.”

For decades, Perin has followed in THI founder Denton Cooley’s footsteps with world-changing research. In 2001, the founding medical director of THI’s Stem Cell Center was the first person to inject stem cells into a failing human heart. It led to a trial of 17 patients that year.

“A couple of the patients did remarkably well — more than you could ever expect. These guys who couldn’t’ walk across the room pretty much were jogging on the beach. That gave me the initial insight that this works,” Perin recalls.

What exactly is heart failure? The term refers to the condition of a heart that can’t pump enough blood to sustainably power the body through oxygenation of the tissues from blood flow. It may sound like a death sentence, but with appropriate care, it can usually be managed with medicines and if worsening occurs, devices and, ultimately, heart transplantation.

And Perin is proving that there’s a lot of life ahead for heart failure patients. Earlier this year, he published another groundbreaking clinical trial, DREAM-HF. The largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America.

With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.

“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.

But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.

These are blockbuster numbers, and big news for patients dealing with heart failure. What it means is that the cells addressed a different aspect of heart failure that until now had been left untreated which was the inflammation — how heart failure starts and what keeps it going.

So what’s next? Going to the FDA.

“They said, ‘We can’t approve it with one trial, but we’ll approve it with two,’” says Perin.

This time, his primary endpoint will be tailored to suit the positive outcome he knows he’ll be able achieve. This next round will begin in 2024.

Once the FDA approves a new catheter system for injecting the heart with stem cells and genes, the team will proceed with new studies. Gene therapy will be another frontier for Perin — and patients with heart failure.

“I think the combination of cells and genes is even more powerful,” he says. “That will help save lives in a completely new way and do away with heart failure.”

Perin's work is just one piece of the puzzle, and Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, is leading the organization's initiative in several ways. THI, recently buoyed by a $32 million donation from a patient — the largest charitable donation in its history — is exploring several innovative therapeutics, devices, and treatments.

THI recently received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis. Another THI innovator, Camila Hochman-Mendez — along with her research team — is studying the effects of regenerative medicine on hearts.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Announcing the 2026 Houston Innovation Awards finalists

Inspirational Innovators

InnovationMap is proud to reveal the finalists for the 2026 Houston Innovation Awards.

The sixth annual Houston Innovation Awards program returns in an all-digital format this fall to honor the best of Houston's innovation ecosystem, including startups, entrepreneurs, mentors, and more.

Finalists were determined by our esteemed panel of judges, comprised of past award winners and InnovationMap editorial leadership.

The panel reviewed applications across 10 prestigious categories to determine our finalists. They will select the winner for each category, except for Startup of the Year, which will be chosen by the public via online voting launching later this month.

We will announce the honoree of our annual Trailblazer Award in the coming weeks, then stay tuned as we unveil all of this year's winners on InnovationMap.com in mid-November.

Get to know our finalists in more detail through editorial spotlights leading up to the winner announcement. Without further ado, here are the 2026 Houston Innovation Awards finalists:

Minority-founded Business

Honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation:

  • AI Made Fun
  • Deep Anchor Solutions
  • HEXAspec
  • Prana Surgical
  • Torres Orbital Mining Inc.

Female-founded Business

Honoring an innovative startup founded or co-founded by a woman:

  • Adair
  • ARIX Technologies
  • Bairitone Health
  • FlowCellutions
  • ParaDocs Health

Energy Transition Business

Honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy and beyond:

  • Capwell Services
  • FlowCellutions
  • Hertha Metals
  • Mars Materials
  • Solidec

Health Tech Business

Honoring an innovative startup within the health and medical technology sectors:

  • Bairitone Health
  • InformAI Inc.
  • Prana Surgical
  • Skybound MedTech

Deep Tech Business

Honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics and space sectors:

  • Casimir
  • Focis AI
  • Machine Saver Inc.
  • Square Robot
  • Venus Aerospace

Startup of the Year (People's Choice)

Honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an online voting experience:

  • Fluxworks
  • IronLattice
  • Lumino
  • Progress Report
  • Rosarium
  • Thread
  • TokenRoster

Scaleup of the Year

Honoring an innovative later-stage startup that's recently reached a significant milestone in company growth:

  • Erock
  • Hertha Metals
  • Venus Aerospace

Incubator/Accelerator of the Year

Honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups:

  • Activate
  • Impact Hub Houston
  • MarMo Innovation

Mentor of the Year

Honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs:

  • Al Danto, Rice University
  • Eric Rubenstein, New Climate Ventures
  • Jeremy Pitts, Activate
  • Joe Alapat, Liongard
  • Kyle Judah, Rice University's Liu Idea Lab for Innovation & Entrepreneurship
  • Rachel Bickham, Bickham Services Unlimited LLC

Trailblazer Recipient

  • To be announced

Q&A: TIME100 AI honoree Angle Bush on building Houston’s artificial intelligence future

AI builder

Angle Bush, founder and CEO of Black Women in Artificial Intelligence, has a running question for her organization's members: Are you in the lab?

For Bush, inquiry isn’t philosophical. Learning about artificial intelligence is one thing. But building with it? Developing products, solving problems and creating a stake in the emerging AI economy? That’s another thing entirely—and exactly the point.

Bush’s own path into AI began in 2019 with an unlikely project: a robot named Usher, designed to bring her hot cocoa. She went down what she calls “YouTube University” to figure out how to build it and kept encountering another subject: artificial intelligence. Her curiosity eventually led her to a Houston AI event, where she noticed something missing.

She didn’t see a full reflection of herself, prompting a bigger question: If AI was becoming a transformative force, who would have a role in shaping it? Her answer became the premise for what came next: There couldn’t be an AI revolution without Black women.

Bush never finished Usher. Instead, she built Black Women in Artificial Intelligence, which has grown into a global organization with members across five continents.

Six years after launching BWIAI, the Houston founder was named to the 2026 TIME100 AI, TIME’s annual list recognizing 100 of the world’s most influential people in artificial intelligence.

The recognition is significant, but Bush is focused on what comes next: moving people beyond AI literacy and adoption and into creation—turning ideas into deployed products, building economic opportunity and ensuring more people have a hand in shaping the technology.

That mission brings Bush back to Houston, where she sees an opportunity to build on the city’s entrepreneurial culture while advancing conversations around responsible and ethical AI.

InnovationMap spoke with Bush about her TIME100 AI recognition, her push to get more people building with AI, Houston’s role in the technology’s future and her simple message: Get in the lab.

InnovationMap: What accomplishment at BWIAI are you most proud of?

Angle Bush: This past March, 11 of our members designed and deployed products and services utilizing artificial intelligence. For me, that's what we want to do. We're looking for builders. I continually ask our members: Are you in the lab? What are you building?

We have members here in Houston who built a conference app designed to help people better understand and navigate the conference experience. We also have Shonda and Shalisha Witherspoon, The Digital Twins, who created a patent assistant to help individuals interested in creating a patent for their product or service.

For me, watching those women move dreams from notebooks to deployment is more important than anything else. Notebooks are designed to hold your dreams, but not keep your dreams.

For NVIDIA's GPU Technology Conference, if you wanted to participate as part of the Black Women in AI delegation, you had to build something. You couldn't just give me a concept and say, “Hey, Angle, I'm building ABC.” No. I needed you to design it, build it and deploy it. That will continually be one of the things I'm most proud of.

IM: Why is building so important to you?

AB: I've been saying that from the beginning because I tell people all the time: I can talk all day. We can have this conversation all day. But at the end of the day, are we building? What is the result?

Conversation is great. It can provide insight. But we have to put our hands on products. We have to put our hands on the APIs. We have to put our hands on that knowledge and ask, What do we do with it?

After you learn it, what are you doing with it? Are you going to create an app that helps your family? Are you creating an app that allows you to be part of the AI economy in a way that you can control? We're all going to be part of the AI economy at some point based on our careers and everything else. But what part of it can you control?

IM: What's next for Black Women in Artificial Intelligence?

AB: I want to continue our mission to educate, engage, embrace and empower Black women in AI. I want our organization to serve as an opportunity for women to build. How do we build? How do we understand how to build? How do we move beyond how we've been conditioned and start asking questions—not only of ourselves, but also the right questions of corporations?

Long term, I want us to continue building, and then I want us to pass that knowledge and insight down to the next generation. But I also want us to reach back to generations that may not have had this opportunity when they were younger. Maybe they were discouraged from going into STEM when they were younger. I want them to know that you can still build. It doesn't matter what your age is. It doesn't matter what college or university you attended. If you have an idea, we want to democratize AI so that you can build.

IM: BWIAI's story began in Houston. What role do you think Houston can play in the AI boom?

AB: First, I absolutely love Houston. I'm originally from Chicago and was raised in Saginaw, Michigan. But as they say, I got to Houston as quickly as I could. I think Houston has a great opportunity to position itself as a center of excellence for innovation. We have an entrepreneurial spirit and drive that I believe is unmatched.

And as much as we have entrepreneurs, we also have advocates who want to see the ethical use of AI. I think we'll see a rise in entrepreneurship. Houston is already building that ecosystem with the Ion and other entities coming into the fold.

As far as the mark Black Women in Artificial Intelligence will make in Houston, I think we'll bring a different perspective to the city's AI ecosystem. We'll make an impact on the entrepreneurial side, but also on the advocacy side when it comes to the responsible and ethical use of AI, which isn't always talked about.

IM: One of the biggest concerns surrounding AI is its potential to displace workers faster than people can acquire new skills. How should we be thinking about that?

AB: In full transparency, that's a tough question to answer because AI is moving so quickly. There are so many different models and so many different things happening that it can appear as though they're coming out of thin air.

For me, it's a matter of how we work with individuals so they can think more about the system than the model, because the models can retire. The impact this is going to have on communities globally is going to be an interesting dynamic. With the work we're doing at Black Women in Artificial Intelligence, this is our mitigation system: How can we bring individuals along so they can learn artificial intelligence and understand that there is a pivot—and it's not coming. It's happening right now, live.

How can we create an ecosystem where individuals get the training, support and understanding they need? For me, that's how we mitigate it: by creating a space where individuals can learn how to pivot.

IM: If readers take one thing away from this conversation, what do you want it to be?

AB: How important it is to be in the lab. It is important to start building today—not tomorrow, not next week, not next month. We have to be in the lab today. That's it.

This interview has been edited for brevity and clarity.

UTMB launches new department for space medicine, names inaugural leader

department launch

In space, no one can hear you scream—but they can hear you discuss your medical history and recent symptoms.

The University of Texas Medical Branch (UTMB) announced last month that it would form a new Department of Aerospace and Exploration Medicine within its School of Public and Population Health under the leadership of Dr. Ronak V. Shah, who will serve as inaugural chair.

“Human exploration is changing rapidly, and the health challenges associated with distance, isolation, and limited resources are changing along with it,” Shah said in a news release. “Creating the Department of Aerospace and Exploration Medicine gives us an opportunity to build on decades of expertise at UTMB as we prepare for the future.”

The new department elevates UTMB’s existing Aerospace Medicine Division and provides "broader academic structure for expanding research, education, and collaboration across disciplines," according to the release. Shah was previously named director of the division in 2022 after serving as medical director of Johnson Space Center.

Space exploration in particular has a wide variety of highly specific medical side effects that are in need of the formalized study that the department will specialize in. For example, zero- and low-gravity environments cause everything from detached fingernails to flattened eyeballs. Even in modern, high-tech spacecraft, the human body feels the impacts of space.

It’s an area of medicine UTMB is uniquely suited for. Starting in the 1950s with NASA’s director of medical research Dr. Charles A. Berry, UTMB partnered with the blossoming era of exploration by monitoring astronauts. In 1993, UTMB and the NASA Johnson Space Center created the joint Aerospace Medicine Residency Program, which used bed facilities at the Galveston branch to simulate weightlessness. Wherever there has been a question about how flight and space affect health, odds are UTMB has been involved.

The Department of Aerospace and Exploration Medicine will launch several new initiatives soon. One planned for 2027 is an Undersea and Hyperbaric Medicine Fellowship that will allow scientists to study the physiology of high-pressure flight.

“In the era of a growing global space economy, we are revisiting questions such as who is flying, what is their destination, what vehicle will get them there?” Shah added in the release. “The answers to these questions will drive what research is needed and how we train the next generation.”

View All Listings